Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
10.03
-0.27 (-2.62%)
At close: Nov 16, 2026, 4:00 PM EST
10.18
+0.15 (1.50%)
After-hours: Nov 16, 2026, 7:30 PM EST
Keros Therapeutics Employees
Keros Therapeutics had 87 employees as of September 30, 2026. The number of employees increased by 5 or 6.10% compared to the same quarter last year. That makes Keros Therapeutics the 32,307th largest employer in the world and 4,163rd in the United States.
Employees
87
Change (1Y)
5
Growth (1Y)
6.10%
Revenue / Employee
$468,517
Profits / Employee
-$709,494
Market Cap
196.83M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 87 | 5 | 6.10% |
| Jun 30, 2026 | 92 | -56 | -37.84% |
| Mar 31, 2026 | 87 | -76 | -46.63% |
| Dec 31, 2025 | 78 | -91 | -53.85% |
| Sep 30, 2025 | 82 | -78 | -48.75% |
| Jun 30, 2025 | 148 | -1 | -0.67% |
| Mar 31, 2025 | 163 | 22 | 15.60% |
| Dec 31, 2024 | 169 | 33 | 24.26% |
| Sep 30, 2024 | 160 | 31 | 24.03% |
| Jun 30, 2024 | 149 | 28 | 23.14% |
| Mar 31, 2024 | 141 | 34 | 31.78% |
| Dec 31, 2023 | 136 | 31 | 29.52% |
| Sep 30, 2023 | 129 | 25 | 24.04% |
| Jun 30, 2023 | 121 | 24 | 24.74% |
| Mar 31, 2023 | 107 | 32 | 42.67% |
| Dec 31, 2022 | 105 | 45 | 75.00% |
| Sep 30, 2022 | 104 | 59 | 131.11% |
| Jun 30, 2022 | 97 | 53 | 120.45% |
| Mar 31, 2022 | 75 | 37 | 97.37% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Entrada Therapeutics | 152 |
| Artiva Biotherapeutics | 134 |
| AC Immune | 122 |
| Compugen | 75 |
| Cartesian Therapeutics | 75 |
| Korro Bio | 58 |
| Pyxis Oncology | 56 |
KROS News
- 5 hours ago - Keros Therapeutics authorizes additional $5M share repurchase - TheFly
- 6 hours ago - Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization - GlobeNewsWire
- 16 hours ago - Keros Therapeutics price target raised to $18 from $17 at BofA - TheFly
- 11 days ago - Keros Therapeutics reports Q3 EPS 70c, consensus (86c) - TheFly
- 11 days ago - Keros Therapeutics Earnings release: Q3 2026 - Filings
- 11 days ago - Keros Therapeutics Quarterly report: Q3 2026 - Filings
- 27 days ago - Keros Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 6 weeks ago - Keros Therapeutics to receive $20M development milestone payment from Takeda - TheFly